174 related articles for article (PubMed ID: 23486350)
1. Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount.
Schiavo M; Bagnara MC; Pomposelli E; Altrinetti V; Calamia I; Camerieri L; Giusti M; Pesce G; Reitano C; Bagnasco M; Caputo M
Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):301-7. PubMed ID: 23486350
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of radioiodine therapy in multinodular toxic goiter, applying an implemented dose calculation algorithm.
Schiavo M; Bagnara MC; Camerieri L; Pomposelli E; Giusti M; Pesce G; Reitano C; Caputo M; Bagnasco M
Endocrine; 2015 Apr; 48(3):902-8. PubMed ID: 25151403
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
4. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.
Ceccarelli C; Bencivelli W; Vitti P; Grasso L; Pinchera A
Clin Endocrinol (Oxf); 2005 Mar; 62(3):331-5. PubMed ID: 15730415
[TBL] [Abstract][Full Text] [Related]
5. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
7. GATE based Monte Carlo simulation of planar scintigraphy to estimate the nodular dose in radioiodine therapy for autonomous thyroid adenoma.
Hammes J; Pietrzyk U; Schmidt M; Schicha H; Eschner W
Z Med Phys; 2011 Dec; 21(4):290-300. PubMed ID: 21983024
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
9. An analytical model for improving absorbed dose calculation accuracy in non spherical autonomous functioning thyroid nodule.
Amato E; Lizio D; Ruggeri RM; Raniolo M; Campennì A; Baldari S
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):560-6. PubMed ID: 21242948
[TBL] [Abstract][Full Text] [Related]
10. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
[TBL] [Abstract][Full Text] [Related]
11. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
[TBL] [Abstract][Full Text] [Related]
12. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
Traino AC; Di Martino F; Lazzeri M
Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
[TBL] [Abstract][Full Text] [Related]
13. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
14. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
Traino AC; Grosso M; Mariani G
Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
[TBL] [Abstract][Full Text] [Related]
15. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule.
Zakavi SR; Mousavi Z; Davachi B
Nucl Med Commun; 2009 Feb; 30(2):169-75. PubMed ID: 19194214
[TBL] [Abstract][Full Text] [Related]
17. Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodules.
Jentzen W; Görges R; Freudenberg L; Eising EG; Müller SP; Bockisch A
Nucl Med Commun; 2008 Apr; 29(4):398-404. PubMed ID: 18317306
[TBL] [Abstract][Full Text] [Related]
18. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
[TBL] [Abstract][Full Text] [Related]
19. A dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction.
Traino AC; Di Martino F
Phys Med Biol; 2006 Dec; 51(24):6449-56. PubMed ID: 17148828
[TBL] [Abstract][Full Text] [Related]
20. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
